Immuneering said it will present new preclinical data at SITC2026 showing atebimetinib may enhance PD-1 checkpoint blockade in RAS-mutant tumor models. The update extends earlier data showing reduced tumor volume and preserved body mass in pancreatic cancer models.
published
Immuneering said it will present new preclinical data at SITC2026 showing atebimetinib may enhance PD-1 checkpoint blockade in RAS-mutant tumor models. The update extends earlier data showing reduced tumor volume and preserved body mass in pancreatic cancer mo
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.